儿童期电离辐射暴露与淋巴瘤及多发性骨髓瘤风险的队列分析
该研究汇总了9个儿童期(<21岁)外照射辐射暴露队列,随访平均42.1年,共143,136人,分析淋巴系统肿瘤死亡与发病风险。结果显示淋巴瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、慢性淋巴细胞白血病及多发性骨髓瘤的辐射超额相对风险均无显著增加,仅淋巴组织剂量分析中部分终点呈边缘显著。
要点
- 儿童期辐射暴露后淋巴瘤及多发性骨髓瘤风险无显著增加
- 平均红骨髓剂量0.14 Gy,平均首次暴露年龄6.93岁
- 淋巴组织剂量分析中NHL+CLL、NHL、CLL风险呈边缘显著
核心结论
- 儿童期外照射辐射暴露后淋巴瘤、霍奇金淋巴瘤、非霍奇金淋巴瘤、慢性淋巴细胞白血病及多发性骨髓瘤风险无显著增加。
- 淋巴组织剂量分析中NHL+CLL、NHL和CLL风险呈边缘显著增加(p-trend=0.02-0.07)。
研究设计与样本
- 汇总9个首次外照射暴露年龄<21岁的队列,入组年份1916-1981年,共143,136人,平均随访42.1年。
- 使用活性骨髓剂量及可获得的淋巴系统剂量,统一结局分类,拟合相对与绝对风险模型。
主要发现
- 随访期间共593例淋巴瘤死亡及发病(422例NHL、107例HL、64例亚型不确定)、66例CLL和122例MM。
- 淋巴瘤ERR/Gy=-0.001(95%CI:-0.255,0.279),HL ERR/Gy=-0.113(95%CI:-0.669,0.709)。
- NHL+CLL ERR/Gy=0.099(95%CI:-0.149,0.433),NHL ERR/Gy=0.068(95%CI:-0.253,0.421)。
- CLL ERR/Gy=0.320(95%CI:-0.678,1.712),MM ERR/Gy=0.149(95%CI:-0.513,1.063),所有p-trend>0.4。
关键数值与推荐
- 平均活性骨髓剂量0.14 Gy(范围0-5.95 Gy),平均首次暴露年龄6.93岁。
- 淋巴组织剂量分析(6个队列)中NHL+CLL、NHL、CLL的p-trend分别为0.02-0.07。
临床怎么用
- 对于儿童期接受电离辐射暴露者,淋巴瘤及多发性骨髓瘤风险未见显著升高,可据此进行风险沟通。
- 淋巴组织剂量相关边缘信号提示需关注NHL、CLL风险,但尚不足以改变筛查策略。
局限性
- 需要更长随访、由专家血液病理学家进行中心化结局复核,并评估淋巴组织辐射剂量的进一步汇总流行病学研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is limited evidence that non-leukaemic lymphoid malignancies are radiogenic. As radiation-related cancer risks are generally higher after childhood exposure, we analysed pooled lymphoid neoplasm data in nine cohorts first exposed to external radiation aged <21 years using active bone marrow (ABM) and, where available, lymphoid system doses, and harmonised outcome classification. Relative and absolute risk models were fitted. Years of entry spanned 1916-1981. At the end of follow-up (mean 42.1 years) there were 593 lymphoma (422 non-Hodgkin (NHL), 107 Hodgkin (HL), 64 uncertain subtype), 66 chronic lymphocytic leukaemia (CLL) and 122 multiple myeloma (MM) deaths and incident cases among 143,136 persons, with mean ABM dose 0.14 Gy (range 0-5.95 Gy) and mean age at first exposure 6.93 years. Excess relative risk (ERR) was not significantly increased for lymphoma (ERR/Gy = -0.001; 95% CI: -0.255, 0.279), HL (ERR/Gy = -0.113; 95% CI: -0.669, 0.709), NHL + CLL (ERR/Gy = 0.099; 95% CI: -0.149, 0.433), NHL (ERR/Gy = 0.068; 95% CI: -0.253, 0.421), CLL (ERR/Gy = 0.320; 95% CI: -0.678, 1.712), or MM (ERR/Gy = 0.149; 95% CI: -0.513, 1.063) (all p-trend > 0.4). In six cohorts with estimates of lymphatic tissue dose, borderline significant increased risks (p-trend = 0.02-0.07) were observed for NHL + CLL, NHL, and CLL. Further pooled epidemiological studies are needed with longer follow-up, central outcome review by expert hematopathologists, and assessment of radiation doses to lymphoid tissues.
引用
- Little MP, Wakeford R, Zablotska LB, et al. Lymphoma and multiple myeloma in cohorts of persons exposed to ionising radiation at a young age. Leukemia. 2021. PMID: 34050261. doi:10.1038/s41375-021-01284-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。